Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) PT at $100.20

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $100.20.

Several analysts have issued reports on the company. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Monday, November 10th. Barrington Research restated an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Wells Fargo & Company dropped their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, November 5th.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $87.78 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of 37.84, a P/E/G ratio of 1.95 and a beta of 0.72. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $105.55. The firm’s 50-day simple moving average is $84.75 and its two-hundred day simple moving average is $87.83.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in LMAT. M&T Bank Corp raised its holdings in LeMaitre Vascular by 2,240.5% during the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after buying an additional 381,061 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in LeMaitre Vascular by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after buying an additional 231,157 shares during the period. First Trust Advisors LP boosted its stake in LeMaitre Vascular by 35.4% during the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock worth $72,541,000 after acquiring an additional 216,919 shares in the last quarter. Millennium Management LLC grew its stake in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after buying an additional 115,141 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 20.1% during the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after acquiring an additional 105,921 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.